Extra radiation boost for high-risk prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This Phase 2 study tests a treatment plan that uses standard focused radiation to the prostate, plus an extra “boost” delivered inside the prostate. It may help improve control of high-risk prostate cancer, especially by aiming radiation more precisely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer confirmed by biopsy (prostate adenocarcinoma).
- Your cancer is considered high-risk, such as stage T3, Gleason score 8–10, or PSA over 20.
- You are willing and able to sign informed consent to join the study.
- You have not had prior radiation therapy to the pelvic area.
- You are able to safely receive radical prostate radiotherapy and prostate MRI.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding a stronger “boost” dose of targeted radiation (SBRT) can better control higher-risk prostate cancer. It may help by increasing radiation coverage to the prostate while trying to limit treatment to surrounding areas.
This trial tests whether two “ablative” (high-dose, focused) radiation treatments can work well for men with favorable-risk prostate cancer. It looks at whether the treatments are practical and safe, especially for urinary side effects.
This trial tests a special type of radiation therapy (SBRT) that delivers a higher dose directly to the main tumor in your prostate, guided by a PSMA PET scan. It aims to improve cancer control while limiting side effects.
This trial studies a type of focused radiation (“ablative radiotherapy”) for prostate tumors considered intermediate- or high-risk. It may help improve control of the cancer while aiming for acceptable side effects.
This trial tests a newer, more precise radiation treatment that gives a higher dose to the main tumor while keeping radiation to the rest of the prostate the same. It is for men with intermediate- or high-risk prostate cancer who haven't had prior prostate radiation or removal.
This trial tests whether giving higher radiation doses to the prostate and pelvic lymph nodes is more effective than treating only the prostate. You may benefit if your prostate cancer has spread to nearby lymph nodes but not to bones or other organs, and you are getting hormone therapy.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.